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Abstract
 
Protein kinase Cs (PKCs) are activated by antigen receptors in lymphocytes, but little is known
about proximal targets for PKCs in antigen receptor–mediated responses. In this report, we de-
fine a role for diacylglycerol-regulated PKC isoforms in controlling the activity of the serine/
 
threonine kinase protein kinase D (PKD; also known as PKC
 
m
 
) in T cells, B cells, and mast
cells. Antigen receptor activation of PKD is a rapid and sustained response that can be seen in T
cells activated via the T cell antigen receptor, B cells activated via the B cell antigen receptor,
and in mast cells triggered via the high-affinity receptor for IgE (Fc
 
e
 
R1). Herein, we show that
antigen receptor activation of PKD requires the activity of classical/novel PKCs. Moreover,
PKC activity is sufficient to bypass the requirement for antigen receptor signals in the induc-
tion of PKD activity. These biochemical and genetic studies establish a role for antigen recep-
tor–regulated PKC enzymes in the control of PKD activity. Regulation of PKD activity
through upstream PKCs reveals a signaling network that exists between different members of
the PKC superfamily of kinases that can operate to amplify and disseminate antigen receptor
signals generated at the plasma membrane.
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Introduction
 
Antigen receptors control a network of signaling events that
regulate lymphocyte function (1–4). Triggering of antigen
receptors activates cytosolic tyrosine kinases that couple an-
tigen receptors to a variety of different signaling molecules,
 
including phospholipase C
 
g
 
1
 
 (PLC)
 
1
 
 
 
g
 
1
 
. The activation of
PLC
 
g
 
1
 
 results in the hydrolysis of phosphatidylinositol
(4,5)P
 
2
 
, producing inositol polyphosphates and diacylglyc-
erol (DAG), which regulate intracellular calcium levels and
activate the protein kinase C (PKC) family of serine/threo-
nine kinases, respectively. Activation of PKCs is critical for
leukocyte function. Targets for PKCs in lymphocytes in-
clude transcription factors such as nuclear factor 
 
k
 
B (5),
which are important for the regulation of cytokine gene
expression. There is also evidence that PKCs control inte-
grin function, with obvious implications for the regulation
of lymphocyte adhesion and cell–cell contact (6, 7). The
potency of PKC signaling pathways for lymphocyte activa-
tion is underlined by the observation that phorbol esters,
pharmacological agents that activate PKC, can mimic many
aspects of antigen receptor triggering (8–10).
There are multiple related PKC isoforms, which are clas-
 
sified into three distinct groups: classical PKCs (
 
a
 
, 
 
b
 
I
 
, 
 
b
 
II
 
,
and 
 
g
 
), which are regulated by calcium, DAG, and phos-
pholipids; novel PKCs (
 
d
 
, 
 
e
 
, 
 
h
 
, and 
 
u
 
), which are regulated
by DAG and phospholipids; and the atypical PKCs (
 
z 
 
and
 
l
 
), which are insensitive to both calcium and DAG (11–
13). Mice lacking the classical PKC isoforms PKC
 
b
 
I/II
 
 ex-
hibit B lymphocyte dysfunction and have impaired hu-
moral responses to T cell–independent antigens (14).
Novel PKCs have also been implicated in antigen receptor
function in T cells on the basis that PKC
 
u 
 
localizes to the
plasma membrane contact zone formed between T cells
and APCs during antigen stimulation (15, 16). Neverthe-
less, despite these intriguing localization data, there is little
known about the biochemistry of PKC signaling pathways
in lymphocytes. The present challenge is to identify targets
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for these enzymes that transmit signals to the cell interior
and control the complex genetic processes that ultimately
determine lymphocyte function.
A serine kinase protein kinase D (PKD) has been found
to be highly expressed in hematopoietic cells (17, 18). Sev-
eral important functions have been reported for this kinase,
including the regulation of nuclear factor 
 
k
 
B transcription
factors and in the control of Golgi complex organization
and protein transport processes (19–21). PKD is distantly re-
lated to the PKC family through the presence of a con-
served DAG-binding cysteine-rich domain (C1 domain)
within its regulatory domain (17, 22, 23). However, the
catalytic domain of PKD shows very low homology to the
conserved kinase subdomains of the PKCs (17) and displays
a unique substrate specificity (17, 23). PKD is highly ex-
pressed in both T and B lymphocytes, and antigen receptor
engagement rapidly stimulates PKD activity (24, 25). The
mechanism for activation of PKD in lymphocytes is not
known. The C1 domain of PKD can bind DAG, and DAG
production is essential for B cell antigen receptor (BCR)
coupling to PKD (25). The C1 domain of PKD has an es-
sential role in localizing PKD to the plasma membrane in
phorbol etser–activated cells (26). Nevertheless, it is not
clear whether DAG binding directly activates PKD in lym-
phocytes. In this context, studies in fibroblast cell lines have
noted that DAG and phorbol esters do not directly activate
PKD in intact cells (27, 28). Instead, they activate classical
and novel PKC enzymes, which subsequently act to regu-
late the catalytic activity of PKD by inducing the phosphor-
ylation of two critical serine residues within the catalytic
domain of PKD (29, 30). Whether the regulatory mecha-
nisms that control PKD activity in lymphocytes are the
same as those operating in fibroblasts and epithelial cells is
 
unknown. The reason for questioning a universal model for
PKD activation is that PKD exhibits distinct patterns of sub-
cellular localization in different cell types. In epithelial cells,
PKD is localized within the Golgi compartment (20, 31). In
contrast, PKD is found localized to the cytosol of lympho-
cytes, not the Golgi, raising the possibility that the regula-
tory mechanisms that control the activity of this kinase may
be different.
The object of this report was to use genetic and bio-
chemical analysis to examine the regulation of PKD in
lymphocytes, and in particular to study the mechanism of
antigen receptor coupling to PKD. These studies identify a
function for classical/novel PKC enzymes in lymphocytes
as signaling intermediates that couple antigen receptors to
the serine/threonine kinase, PKD.
 
Materials and Methods
 
cDNA Constructs.
 
Constitutively active PKC
 
e
 
 and 
 
h 
 
mutants
(containing pseudosubstate motif deletions) were provided by P.
Parker (Protein Phosphorylation Laboratory, Imperial Cancer
Research Fund, London, UK). cDNA constructs containing
wild-type and P287G mutant PKD sequences in the pcDNA3
mammalian expression vector have been described previously
(23, 32). Chimeric fusion proteins between green fluorescent
protein (GFP) and different PKD mutants were generated by sub-
cloning the PKD constructs into the EcoR1 site of a pEF-plink2-
GFP
 
C3
 
 expression vector. All constructs were purified by CsCl
density gradient centrifugation before use in transient transfection
experiments.
 
Cell Culture and Transient Transfection. 
 
The murine BALB/c
mouse B lymphoma A20 cell line was maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum and 50 
 
m
 
M
 
b
 
-mercaptoethanol. The rat basophilic leukemia (RBL) cell line
Figure 1. BCR or FceR1 ligation induces PKD catalytic activity. (A) Left: A20 B lymphocytes were left untreated (n/s) or were stimulated with 10
mg/ml F(ab)92 fragments of anti–mouse IgG for various amounts of time (0–10 min) to activate the BCR complex. Alternatively, the cells were stimu-
lated with 50 ng/ml PDBu for 10 min. The cells were subsequently lysed before PKD was immunoprecipitated using the PA-1 antiserum, and in vitro
kinase assays were performed. PKD activity was measured by autophosphorylation (IVK). In parallel, total proteins from the cell lysates were precipitated
with cold acetone, separated by SDS-PAGE, and subjected to Western blot analysis using the pS916 antiserum and a pan–COOH-terminal PKD anti-
body. Results are representative of four independent experiments. Right: the mean 6 SE (n 5 4) increase in PKD activity over time after BCR ligation
(as measured by autophosphorylation [IVK] or by immunoreactivity with the pS916 antiserum) is shown, expressed as the fold increase in PKD activity
over basal levels in nonstimulated cells. (B) RBL 2H3 cells were primed with 1 mg/ml IgE anti-DNP for 1 h at 378C, and then either antigenic cross-
linking of the bound IgE was performed using 500 ng/ml KLH-DNP for various amounts of time (0–10 min), or the cells were left unstimulated (2).
Alternatively, RBL 2H3 cells were stimulated with 50 ng/ml PDBu for 10 min. PKD was immunoprecipitated from whole cell lysates, and the activity
of PKD was measured by in vitro kinase assays (IVK). SDS-PAGE and Western blot analysis of the cell lysates show equivalent amounts of PKD in all the
samples. Results are representative of two independent experiments. a-, anti-. 
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2H3 was maintained as described previously (33). Human periph-
eral blood–derived T lymphoblasts were generated and main-
tained as described previously (34). The Jurkat T lymphocyte cell
line JH6.2 was maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum. For transient expression of cDNA
constructs, 1.5 
 
3
 
 10
 
7
 
 A20 B cells or RBL 2H3 cells were elec-
troporated with 20 
 
m
 
g of DNA at 310 V and 960
 
 m
 
F, resus-
pended in 5 ml of complete medium, and cultured overnight be-
fore experimental usage.
 
Cell Lysis and Western Blot Analysis.
 
After stimulation, cells
were lysed for 20 min at 4
 
8
 
C in a buffer containing 50 mM Tris/
HCl, pH 7.4; 2 mM EGTA; 2 mM EDTA; 1 mM dithiothreitol;
10 
 
m
 
g/ml aprotinin; 10 
 
m
 
g/ml leupeptin; 1 mM 4-(2
 
9
 
-aminoeth-
yl)-benzenesulfonyl fluoride hydrochloride; and 1% Triton X-100.
Lysates were clarified by centrifugation at 14,000 rpm for 10 min
at 4
 
8
 
C, and proteins in the supernatant were precipitated with
ice-cold acetone and resuspended in 
 
3
 
2 SDS-PAGE sample
buffer. Samples were resolved under reducing conditions by 8%
SDS-PAGE and transferred to polyvinylidene difluoride mem-
branes (Millipore). Western blot analysis was performed, and im-
munoreactive bands were visualized by enhanced chemilumines-
cence.
 
In Vitro Kinase Assays. 
 
Endogenous PKD was immunopre-
cipitated from cell lysates at 4
 
8
 
C for 2 h with the PA-1 antiserum
(1:100 dilution) as described previously (23) and recovered with
protein A–agarose beads. Immunocomplexes were washed twice
in lysis buffer and once in kinase buffer (30 mM Tris/HCl, pH
7.4; 10 mM MgCl
 
2
 
), and PKD activity (as measured by autophos-
phorylation) was determined by incubating immunocomplexes
with 20 
 
m
 
l of kinase buffer containing 100 
 
m
 
M [
 
g
 
-
 
32
 
P]ATP final
concentration at 30
 
8
 
C for 10 min. Reactions were terminated by
the addition of 
 
3
 
2 SDS-PAGE sample buffer, and were analyzed
by SDS-PAGE and autoradiography.
 
Materials.
 
Enhanced chemiluminescence reagents and [
 
g
 
-
 
32
 
P]ATP (370 MBq/ml) were from Amersham Pharmacia Bio-
tech. Phorbol dibutyrate (PDBu) was from Sigma-Aldrich. Pro-
tein A–agarose was from Boehringer. The PKC inhibitors Ro
31-8220 and GF 109203X were from LC Laboratories. A rabbit
polyclonal PKD antibody directed against the COOH terminus
of PKD used for Western blotting was from Santa Cruz Biotech-
nology, Inc. (sc-935). Phospho–extracellular signal–regulated ki-
nase (Erk)-1/2 and pan–Erk-2 antibodies were from Promega
and Transduction Laboratories, respectively. Recombinant hu-
man IL-2 was from Eurocetus. All other reagents were from stan-
dard suppliers, or as indicated in the text.
 
Results and Discussion
 
Activation of PKD in B Lymphocytes, Mast Cells, and T
Lymphocytes after Antigen Receptor Ligation.
 
Previous results
have shown that triggering of the BCR induces PKD cata-
lytic activity (24, 25). The BCR is one of a family of anti-
gen receptors that includes the Fc
 
e
 
R1 and the TCR. These
receptors couple to different cytosolic tyrosine kinases and
have the potential to couple to unique downstream signals.
Therefore, in initial experiments, we examined whether
PKD activation is common to the BCR, the Fc
 
e
 
R1, and
the TCR. PKD activity was monitored by quantitation of
PKD autophosphorylation using in vitro kinase assays. Fur-
thermore, we have recently shown that active PKD auto-
phosphorylates on a COOH-terminal serine residue (S916),
 
and that a specific antiserum recognizing PKD molecules
phosphorylated on S916 can be used to efficiently monitor
the catalytic activity of PKD in intact cells (24).
To study B cell responses, A20 B lymphoma cells were
either left unstimulated or were activated by cross-linking
the BCR with F(ab)
 
9
 
2 fragments of anti–mouse IgG for
various amounts of time (0–10 min). Cross-linking of the
BCR complex was found to induce a rapid 
 
z
 
8-fold in-
crease in PKD catalytic activity, as assessed by in vitro ki-
nase assays that measure PKD autophosphorylation (Fig. 1
A). This response was maximal within 1 min of BCR trig-
gering, and was sustained for 
 
.
 
10 min. In addition to regu-
lating the catalytic activity of PKD, ligation of the BCR
complex was also found to induce autophosphorylation of
the COOH-terminal S916 residue of PKD in a manner that
paralleled the observed increase in PKD catalytic activity.
Thus, Western blot analysis of lysates prepared from
F(ab)
 
9
 
2-treated A20 B lymphoma cells showed a rapid,
strong immunoreactivity of the pS916 antibody for active
PKD present in these cells, but not with PKD isolated from
nonstimulated cells (Fig. 1 A). PKD was also activated
Figure 2.  TCR stimulation
induces PKD catalytic activity.
(A) Peripheral blood T lympho-
blasts were left nonstimulated
(n/s) or were treated with 10 mg/
ml UCHT1 for various amounts
of time (1–10 min) to activate
the TCR complex. Alternatively,
the cells were stimulated with 50
ng/ml PDBu for 10 min. Top:
endogenous PKD was immuno-
precipitated from whole cell ly-
sates using the PA-1 antiserum,
and in vitro kinase assays were
performed. PKD activity was
measured by autophosphoryla-
tion (IVK). Bottom: total pro-
teins from whole cell lysates were
precipitated with cold acetone,
separated by SDS-PAGE, and
subjected to Western blot analy-
sis using a pan–COOH-terminal
PKD antibody. (B) JH6.2 T lym-
phocytes were left nonstimu-
lated (n/s) or were treated with
10 mg/ml UCHT1 for various
amounts of time (1–10 min) to
activate the TCR complex. En-
dogenous PKD was immunopre-
cipitated from whole cell lysates
using the PA-1 antiserum, and in vitro kinase assays (IVK) were per-
formed. PKD expression levels were determined by Western blotting of
cell lysates using a pan–COOH-terminal PKD antibody. Data are repre-
sentative of a least two independent experiments. (C) T lymphocytes were
left nonstimulated (n/s) or were treated with 10 mg/ml UCHT1 or 50
ng/ml PDBu for 10 min. Total proteins from the cell lysates were precip-
itated with cold acetone, analyzed by SDS-PAGE, and subjected to West-
ern blot analysis using the pS916 antiserum, which recognizes active PKD
and a pan–COOH-terminal PKD antibody. a-, anti-. 
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when B cells were treated with phorbol esters, pharmaco-
logical activators of PKC (Fig. 1 A).
The antigen receptor present in mast cells is the high-
affinity receptor for IgE, the Fc
 
e
 
R1. To address whether
the Fc
 
e
 
R1 is also coupled to PKD, RBL 2H3 mast cells
were left unstimulated or treated with IgE plus cognate an-
tigen, KLH-DNP, for various amounts of time. The data
presented in Fig. 1 B indicate that ligation of the Fc
 
e
 
R1 in-
duces a rapid increase in PKD catalytic activity, as mea-
sured by in vitro kinase assays.
To examine the effects of triggering the TCR complex
on the catalytic activity of PKD, quiescent human periph-
eral blood–derived T lymphoblasts were activated with the
CD3
 
e 
 
cross-linking mAb UCHT1. As demonstrated in
Fig. 2 A, PKD exhibited a low basal level of kinase activity
in quiescent peripheral T lymphocytes that was rapidly en-
 
hanced after cross-linking of the TCR complex with the
CD3
 
e
 
 antibody UCHT1. Here, maximal stimulation of
PKD catalytic activity was observed within 
 
z
 
1 min of
stimulation, and was sustained for 
 
.
 
10 min. The data in
Fig. 2 B shows that activation of PKD by the TCR com-
plex was also observed in the leukemic Jurkat T cell line,
JH6.2. These cells were stimulated with the UCHT1 mAb,
and PKD activity was measured by in vitro kinase assays.
PKD exhibited negligible basal activity in nonstimulated
JH6.2 cells, and stimulation of the TCR complex led to a
rapid increase in PKD activity, similar to that observed in
peripheral blood–derived T cells.
 
IL-2 Does Not Activate PKD in T Lymphocytes.
 
Hemato-
poietic cytokines such as IL-2 control T cell proliferation
and differentiation. Several TCR-activated serine kinases
are also activated by the IL-2 receptor, including the mito-
gen-activated protein kinases (35) and the phosphatidyl-
inositol 3-kinase–dependent serine kinase PKB/Akt (36).
However, IL-2 activation of classical and novel PKCs has
not been generally observed. The data presented in Fig. 3
demonstrate that IL-2 stimulation of peripheral blood–
derived T lymphoblasts does not increase PKD catalytic activ-
ity over basal levels. In contrast, a phospho-Erk polyclonal
antibody (which specifically recognizes activated Erk-1/2
in Western blot analysis of whole cell lysates) reacted
strongly with active Erks present in both IL-2– and PDBu-
treated cells (Fig. 3), confirming the biological activity of
the IL-2. Similar results were obtained after Western blot
analysis with the pS916 antisera: here, even prolonged
stimulation of peripheral blood–derived T lymphoblasts
with IL-2 for 
 
.
 
1 h did not activate PKD (data not shown).
These experiments indicate that activation of PKD in T
cells is a selective response to antigen receptor triggering
and is not a general response to mitogenic stimuli.
 
PKD Activation by Antigen Receptors Is Not Regulated by
Direct Binding of DAG in Intact Cells.
 
Previous work has
shown that antigen receptor activation of PKD in B cells is
Figure 3. IL-2 does not regulate PKD activity in T lymphocytes (A)
Peripheral blood T lymphoblasts were left nonstimulated (–) or were
treated with either 50 ng/ml PDBu for 10 min or with 20 ng/ml recom-
binant IL-2 (rIL-2) for 2 or 15 min, as indicated. Left: endogenous PKD
was immunoprecipitated from whole cell lysates using the PA-1 antise-
rum, and in vitro kinase assays (IVK) were performed. Extracts from cell
lysates were also analyzed by Western blotting with a pan–COOH-termi-
nal PKD antibody. Right: lysates from the recombinant IL-2 (rIL-2)– or
PDBu-treated T lymphoblasts were also analyzed by Western blotting
with a phosphorylation state–specific Erk-1/2 antibody, and subsequently
with a pan–Erk-2 antibody. Data are representative of three independent
experiments. (B) Peripheral blood T lymphoblasts were left nonstimu-
lated (2) or were treated with either 10 mg/ml UCHT1 or 20 ng/ml re-
combinant IL-2 (rIL-2) for the indicated amount of time. Total proteins
from the cell lysates were precipitated with cold acetone, analyzed by
SDS-PAGE, and subjected to Western blot analysis using the pS916 anti-
serum (which recognizes active PKD), a pan–COOH-terminal PKD an-
tibody, a specific phosphoserine (Ser473) PKB antibody, and a pan-PKB
antibody. a-, anti-.
Figure 4. Direct DAG binding is not essential for PKD activation in
intact cells. A20 B lymphocytes were transiently transfected with 20 mg of
GFP-tagged wild-type (WT) or P287G PKD cDNA. After 16 h incuba-
tion at 378C, the cells were left nonstimulated (2) or were treated with
10 mg/ml F(ab)92 fragments of anti–mouse IgG for the indicated amounts
of times to activate the BCR complex. Ectopically expressed PKD was
immunoprecipitated from cell lysates using a monoclonal GFP antibody
(Imperial Cancer Research Fund), and PKD activity (autophosphoryla-
tion) was measured by in vitro kinase assays (IVK). In addition, expression
levels of the GFP-PKD constructs were verified by Western blot analysis
with a pan–COOH-terminal PKD antibody. Data are representative of
two individual experiments. a-, anti-. 
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dependent on PLC
 
g
 
1
 
 activation (25). The regulatory do-
main of PKD contains a C1 domain that is capable of bind-
ing DAG and that mediates translocation of the enzyme to
the plasma membrane after antigen receptor engagement.
In vitro, DAG and acidic phospholipids can activate PKD
synergistically (18, 23), but in intact lymphocytes the im-
portance of DAG binding to the C1 domain of PKD for
enzyme activation by antigen receptors is not known. The
C1 domain in PKD contains two cysteine-rich motifs
(C1A and C1B) that are not functionally equivalent: C1B
acts as the major DAG binding site within PKD both in
vitro and in vivo (32). A highly conserved proline residue is
conserved in all DAG-binding C1 domains described to
date and is essential for high-affinity binding of DAG or
phorbol esters to these domains. Accordingly, a single
amino acid substitution (P287G) within the C1B motif of
PKD inhibits phorbol ester binding in vitro and in vivo
(32). In this study, we used the PKD P287G mutant to ex-
plore the role of the C1 domain in antigen receptor–medi-
ated PKD activation.
A20 B cells were transiently transfected with either wild-
type PKD or the P287G mutant of PKD. The loss of in
vivo DAG/phorbol ester binding to the PKD P2887G mu-
tant is demonstrated by the inability of this mutant to trans-
locate to the plasma membrane in response to antigen re-
ceptor stimulation or phorbol ester treatment. The data
presented in Fig. 4 compare the activity of wild-type PKD
and the PKD P287G mutant and demonstrate that PKD
Figure 5. Inhibition of classical/novel PKCs prevents activation of PKD by the BCR, the TCR, and the FceR1. (A) A20 B lymphocytes were pre-
treated with 2.5 mm Ro 31-8220 or an equal volume of solvent (2) for 1 h before activation of the BCR complex using 10 mg/ml F(ab)92 fragments of
anti–mouse IgG for the indicated amounts of time. PKD was immunoprecipitated from cell lysates, and PKD activity was measured by in vitro kinase as-
says (IVK) measuring PKD autophosphorylation. Data are expressed as the percentage of the maximal response induced by F(ab)92 alone, and are the
mean 6 SE of three independent experiments. A representative autoradiogram is shown. (B) A20 B lymphocytes were pretreated with 2.5 mm Ro 31-
8220 or an equal volume of solvent (2) for 1 h. The cells were subsequently left nonstimulated (n/s), or were treated with either 10 mg/ml F(ab)92 frag-
ments of anti–mouse IgG for 2 min or with 50 ng/ml PDBu for 10 min. Whole cell lysates were analyzed by Western blotting with the pS916 antiserum
and a pan–COOH-terminal PKD antibody. Similar results were seen in two independent experiments. (C) Peripheral blood–derived T lymphoblasts
were pretreated with 3.5 mM GF 109203X (GF 1 pretreat) or an equal volume of solvent (2) for 1 h. Cells were subsequently left unstimulated (2) or
were treated with 10 mg/ml UCHT1 for various amounts of time, as indicated. PKD was immunoprecipitated from whole cell lysates, and PKD activity
measured by in vitro kinase assays. Data are expressed as the percentage of the maximal response induced by UCHT1 alone and are the mean 6 SE of
three independent experiments. A representative autoradiogram is shown. In some cases, PKD immunoprecipitates were incubated in the presence of 3.5
mM GF 109203X during in vitro kinase assays (GF 1 in vitro). (D) RBL 2H3 mast cells were pretreated with 2.5 mm Ro 31-8220 or an equal volume of
solvent (2) for 1 h before stimulation of the FceR1, as described in the legend to Fig. 1. PKD activity was measured by in vitro kinase assays (IVK). Re-
sults are representative of two independent experiments. a-, anti-.2080 PKC Activates PKD
P287G, when transiently expressed in A20 B lymphocytes,
displays identical kinetics and magnitude of activation as
wild-type PKD after BCR ligation. Thus, the integrity of
the C1 domain is not essential for antigen receptor–medi-
ated activation of PKD in intact cells.
PKD Activation Is Regulated by a PKC Cascade in T Lym-
phocytes, B Lymphocytes, and Mast Cells. The ability of the
BCR to stimulate PKD mutants with defective C1/DAG
binding domains must be reconciled with previous studies
showing that DAG production is essential for PKD activa-
tion (25, 37). Recent studies in fibroblasts have placed
PKD downstream of classical/novel PKC enzymes in a hi-
erarchical signaling cascade regulated by DAG (for reviews,
see references 30, 38). To examine the role of PKCs in the
regulation of PKD by the BCR, A20 cells were preincu-
bated with Ro 31-8220, an inhibitor of classical/novel
PKCs that has no direct inhibitory effect on PKD kinase
activity (28, 39). Subsequently, the BCR complex was ac-
tivated, and PKD activity was measured by in vitro kinase
assays. BCR-induced activation of PKD was severely im-
paired in B lymphocytes that had been pretreated with Ro
31-8220, compared with the marked increase in PKD ac-
tivity observed in control BCR-stimulated cells (Fig. 5 A).
BCR engagement poorly induced PKD S916 phosphoryla-
tion in B lymphocytes that had been pretreated with Ro
31-8220 (Fig. 5 B). Moreover, phorbol ester–induced
PKD S916 phosphorylation was also blocked by the Ro
31-8220 inhibitor (Fig. 5 B).
Subsequent experiments determined whether antigen re-
ceptor–mediated activation of PKD was also regulated via
classical/novel PKCs in T lymphocytes and mast cells. GF
109203X is a second inhibitor of classical and novel PKC
enzymes that also has no direct inhibitory effect on PKD
(28, 39). Peripheral blood–derived T lymphoblasts were
preincubated with GF 109203X, the TCR complex was
activated, and PKD activity was measured by in vitro ki-
nase assays. As indicated in Fig. 5 C, pretreatment of T
lymphoblasts with GF 109203X did not effect the constitu-
tive low basal activity of PKD present in these cells, but se-
verely abrogated TCR-induced activation of PKD. Addi-
tion of this PKC inhibitor directly to PKD during in vitro
kinase assays did not effect the catalytic activity of PKD
(Fig. 5 C), confirming that this inhibitor has no direct ac-
tion towards PKD.
The obligatory role played by classical/novel PKCs in
mediating the activation of PKD by antigen receptors was
also demonstrated in mast cells. Here, pretreatment of RBL
2H3 cells with the PKC inhibitor Ro 31-8220 abrogated
the ability of the FceR1 to induce PKD catalytic activity
(Fig. 5 D). Together, these results indicate that antigen re-
ceptor–induced activation of PKD is regulated through a
PKC-dependent signaling pathway in T and B lympho-
cytes and in mast cells.
PKC Activation Is Sufficient to Induce PKD Activity in Lym-
phocytes. To address whether PKC activity was sufficient
to induce the activation of PKD in lymphocytes, we tran-
siently expressed a constitutively active PKCh mutant in B
lymphocytes and examined its effect on the activity of en-
dogenous PKD. Control A20 B lymphocytes, transfected
with an empty expression vector, exhibited a low basal
level of PKD activity (as shown by Western blotting with
the pS916 antibody) that was markedly enhanced upon
triggering of the BCR complex (Fig. 6 A). In contrast, A20
B cells transfected with the constitutively active PKCh
mutant displayed a high basal level of PKD activity that was
only slightly further enhanced by activation of the BCR
complex (Fig. 6 A). Similar results were observed in the
RBL 2H3 mast cell line, where ectopic expression of con-
stitutively activated mutants of PKCh or PKCe was found
to induce near-maximal PKD activity in the absence of
FceR1 engagement (Fig. 6 B), as measured by in vitro ki-
nase assays. In contrast, control RBL 2H3 cells transfected
with an empty expression vector exhibited a low basal level
of PKD activity (Fig. 6 B). Thus, a PKC-dependent signal-
ing pathway is both required and sufficient to control PKD
activation in lymphocytes.
Conclusions. Historically, PKC enzymes were posi-
tioned in the earliest models of antigen receptor signal
transduction, but there has been little real progress in iden-
tifying targets for PKC signals in lymphocytes. This study
identifies a PKC signaling network in T cells, B cells, and
mast cells that couples antigen receptors to the serine kinase
PKD. The regulatory region of PKD contains a conserved
DAG-binding C1 domain, but the integrity of this domain
is not required for antigen receptor activation of PKD.
Rather, PKD activity is dependent on activation of PKCs;
specifically, inhibitors of classical and novel PKCs (that do
not directly effect PKD activity) block the activation of
PKD after BCR, TCR, or FceR1 ligation. Furthermore,
expression of constitutively active mutants of novel PKC
enzymes (PKCh and PKCe) was sufficient to maximally
stimulate PKD catalytic activity in lymphocytes. The phos-
Figure 6. Constitutively ac-
tive PKC enzyme mutants in-
duce PKD activation. (A) A20 B
lymphocytes were transiently
transfected with 20 mg of either
vector control (V) or activated
PKCh (PKCh*) cDNA. After
16 h of incubation at 378C, the
cells were left nonstimulated (2)
or were treated with 10 mg/ml
F(ab)92 fragments of anti–mouse
IgG for 2 min (1). Whole cell
lysates were analyzed by Western
blotting with the pS916 antise-
rum and a pan–COOH-terminal
PKD antibody. (B) RBL 2H3
mast cells were transiently trans-
fected with 20 mg of either vec-
tor control (V), activated PKCe
(PKCe*), or activated PKCh
(PKCh*) cDNA. After 16 h of incubation at 378C, the cells were left
nonstimulated (2) or were stimulated with IgE plus KLH-DNP
(IgE1KLH-DNP) for 2 min (1). PKD was immunoprecipitated from
cell lysates, and PKD activity was measured by in vitro kinase assays (IVK)
measuring PKD autophosphorylation. All data are representative of two
independent experiments. a-, anti-.2081 Matthews et al.
phorylation of two critical serine residues within the cata-
lytic domain of PKD is essential for activation of this en-
zyme (29, 30). Future studies will determine whether these
sites in PKD are directly phosphorylated by PKC or
whether an intermediate kinase is involved. The role of
PKCs in the regulation of PKD identify a novel mechanism
by which a DAG signal generated by antigen receptor liga-
tion can be disseminated via a PKC to PKD serine kinase
cascade. The data presented here establish PKD as a PKC-
regulated kinase in lymphocytes. Antigen receptors in T
cells, B cells, and mast cells activate unique tyrosine kinases.
They may also activate unique PKC isoforms; PKCb is as-
sociated with BCR function, whereas PKCu is linked to
the TCR signaling. Herein, we establish PKD as a com-
mon downstream target for PKCs in lymphocytes and
identify the PKC/PKD serine kinase cascade as a common
element in antigen receptor signaling.
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